1Q21 Wrap: Sliding down

Biotech stocks lost value in 1Q21, with all tiers $500 million and above losing value, ranging from a 12.5% loss in the $500-$999 million tier to a 1.8% loss for companies $10 billion and above. Microcaps, those starting the quarter valued at $25-$499 million, were the only group to see a median gain, at 8.4%...